| Product Code: ETC6749155 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 China Oncology Active Pharmaceutical Ingredients (APIs) Market Overview |
3.1 China Country Macro Economic Indicators |
3.2 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, 2021 & 2031F |
3.3 China Oncology Active Pharmaceutical Ingredients (APIs) Market - Industry Life Cycle |
3.4 China Oncology Active Pharmaceutical Ingredients (APIs) Market - Porter's Five Forces |
3.5 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume Share, By Manufacturer Type, 2021 & 2031F |
3.7 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume Share, By Type of Synthesis, 2021 & 2031F |
3.8 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume Share, By Indication, 2021 & 2031F |
4 China Oncology Active Pharmaceutical Ingredients (APIs) Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing incidence of cancer cases in China |
4.2.2 Growing demand for oncology APIs due to advancements in cancer treatment |
4.2.3 Favorable government policies supporting the development of the pharmaceutical industry in China |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for API manufacturing and approval |
4.3.2 High costs associated with research and development of oncology APIs |
4.3.3 Competition from established global pharmaceutical companies in the Chinese market |
5 China Oncology Active Pharmaceutical Ingredients (APIs) Market Trends |
6 China Oncology Active Pharmaceutical Ingredients (APIs) Market, By Types |
6.1 China Oncology Active Pharmaceutical Ingredients (APIs) Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Drug Type, 2021- 2031F |
6.1.3 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Innovative Oncology APIs, 2021- 2031F |
6.1.4 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Generic Oncology APIs, 2021- 2031F |
6.2 China Oncology Active Pharmaceutical Ingredients (APIs) Market, By Manufacturer Type |
6.2.1 Overview and Analysis |
6.2.2 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Captive Manufacturers, 2021- 2031F |
6.2.3 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Merchant Manufacturers, 2021- 2031F |
6.3 China Oncology Active Pharmaceutical Ingredients (APIs) Market, By Type of Synthesis |
6.3.1 Overview and Analysis |
6.3.2 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Synthetic Oncology APIs, 2021- 2031F |
6.3.3 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Biotech Oncology APIs, 2021- 2031F |
6.4 China Oncology Active Pharmaceutical Ingredients (APIs) Market, By Indication |
6.4.1 Overview and Analysis |
6.4.2 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Lung Cancer, 2021- 2031F |
6.4.3 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Breast Cancer, 2021- 2031F |
6.4.4 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Colorectal Cancer, 2021- 2031F |
6.4.5 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Prostate Cancer, 2021- 2031F |
6.4.6 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Stomach Cancer, 2021- 2031F |
6.4.7 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Liver Cancer, 2021- 2031F |
6.4.8 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Others, 2021- 2031F |
6.4.9 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenues & Volume, By Others, 2021- 2031F |
7 China Oncology Active Pharmaceutical Ingredients (APIs) Market Import-Export Trade Statistics |
7.1 China Oncology Active Pharmaceutical Ingredients (APIs) Market Export to Major Countries |
7.2 China Oncology Active Pharmaceutical Ingredients (APIs) Market Imports from Major Countries |
8 China Oncology Active Pharmaceutical Ingredients (APIs) Market Key Performance Indicators |
8.1 Research and development expenditure in oncology APIs |
8.2 Number of clinical trials conducted for oncology APIs in China |
8.3 Adoption rate of innovative oncology APIs in the Chinese market |
9 China Oncology Active Pharmaceutical Ingredients (APIs) Market - Opportunity Assessment |
9.1 China Oncology Active Pharmaceutical Ingredients (APIs) Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 China Oncology Active Pharmaceutical Ingredients (APIs) Market Opportunity Assessment, By Manufacturer Type, 2021 & 2031F |
9.3 China Oncology Active Pharmaceutical Ingredients (APIs) Market Opportunity Assessment, By Type of Synthesis, 2021 & 2031F |
9.4 China Oncology Active Pharmaceutical Ingredients (APIs) Market Opportunity Assessment, By Indication, 2021 & 2031F |
10 China Oncology Active Pharmaceutical Ingredients (APIs) Market - Competitive Landscape |
10.1 China Oncology Active Pharmaceutical Ingredients (APIs) Market Revenue Share, By Companies, 2024 |
10.2 China Oncology Active Pharmaceutical Ingredients (APIs) Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here